## FOI 23/277 - adverse events reported to the MHRA concerning patients with inferior vena cava (IVC) filters during MRI exams

## REQUEST 12 April 2023

.. any adverse events with patients with IVC filters during MRI exams covering the period from the 1<sup>st</sup> of January 2022 to today (12/4/2023)

## MHRA REPLY 11 May 2023

Thank you for your email dated 12 April 2023 where you requested information on any adverse events that had been reported to the MHRA concerning patients with inferior vena cava (IVC) filters during MRI exams, covering the period from the 1st of January 2022 to the date you submitted your request.

I can confirm that following a search of our adverse event database the MHRA have not received any adverse incident reports of IVC filters during MRI exams for the period of 1<sup>st</sup> of January 2022 to 3<sup>rd</sup> May 2023.

- Please note that this information is accurate at the time we conduct the search on our database, changes in the number of adverse events can occur following receipt of additional information.
- In addition, the use of our <u>Yellow Card scheme</u> by healthcare professionals and members of the public are voluntary and therefore do not provide absolute adverse event figures.

We hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address.

Yours sincerely,

FOI Team Safety and Surveillance Medicines and Healthcare products Regulatory Agency

The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to access to MHRA information.

For information on the reproduction or re-use of MHRA information, please visit <u>https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information</u>

If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at: Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire SK9 5AF.